Statin therapy for preventing cardiovascular diseases in patients treated with tacrolimus after kidney transplantation

Nayoung Han, Seung Hee Han, Yun Kyoung Song, Myeong Gyu Kim, Yon Su Kim, In Wha Kim, Jung Mi Oh

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


Background: Lipid abnormalities are prevalent in tacrolimus-treated patients. The aim of the study was to evaluate the preventive effects of statin therapy on major adverse cardiovascular events (MACE) in patients treated with tacrolimus-based immunosuppression after kidney transplantation (KT), and to identify the risk factors. Methods: This observational cohort study included adult patients who underwent KT and were treated with tacrolimus. Patients who received any lipid-lowering agents except statins, or had a history of immunosuppressant use before transplantation were excluded. The primary outcome was the adjusted risk of the first occurrence of MACE. The secondary outcomes included the risk of individual cardiovascular disease (CVD) and changes in cholesterol level. Subgroup analyses were performed in the statin-user group according to the dosage and/or type of statin. Results: Compared with the control group (n=73), the statin-users (n=92) had a significantly reduced risk of MACE (adjusted HR, 0.31; 95% CI, 0.13–0.74). In the Cox regression analysis, old age, history of CVD, and comorbid hypertension were identified as independent factors associated with increased MACE. The total cholesterol levels were not significantly different between the two groups. Subjects with higher cumulative defined daily dose of statins had significantly lower risks of MACE. Conclusion: Statin therapy in patients treated with tacrolimus after KT significantly lowered the risk of MACE. Long-term statin therapy is clearly indicated in older kidney transplant recipients for secondary prevention.

Original languageEnglish
Pages (from-to)1513-1520
Number of pages8
JournalTherapeutics and Clinical Risk Management
StatePublished - 21 Nov 2017

Bibliographical note

Funding Information:
This research was supported by a grant from the Korea Health technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number: HC15C1045).

Publisher Copyright:
© 2017 Han et al.


  • HMG-CoA reductase inhibitors
  • Kidney transplantation
  • Major adverse cardiovascular events (MACE)
  • Tacrolimus


Dive into the research topics of 'Statin therapy for preventing cardiovascular diseases in patients treated with tacrolimus after kidney transplantation'. Together they form a unique fingerprint.

Cite this